Dynavax Technologies Corporation(DVAX)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $9.60 – $15.73
- YTD
- +0.75%
- IV Rank (30D)
- 4.27
- Straddle Price
- $3.08
- P/C Vol Ratio
- 3.63
- Market Cap
- $1.8B
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $1.8B
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adap…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Strong technical momentum signals
- Low volatility compared to market
- Recent news headline regarding Sanofi's acquisition of Dynavax Technologies Corporation (DVAX) has a neutral sentiment
Primary Risks:
- Overbought RSI and Stochastic Oscillators indicating potential reversal
- High IV rank suggesting historical volatility is high, which may lead to increased price swings
Investment Thesis: The stock is currently experiencing strong technical momentum, with multiple indicators aligned. However, the recent news headline regarding the acquisition has a neutral sentiment, which may not have significant impact on the stock's price movement.
Recent News Sentiment Impact: The recent news headline has a neutral sentiment, which suggests that it may not have a significant impact on the stock's price movement. The neutral sentiment also indicates that the market is not strongly reacting to this news, which may be a sign of caution for investors.
Technical Analysis
- Trend Direction: Short-term: UPTREND (1-4 weeks), Medium-term: UPTREND (1-3 months), Long-term: UPTREND (3-12 months)
- Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- Upper Bollinger Band: $14.06
- Middle Band: $11.37
- Lower Band: $8.68
- Momentum Signals:
- RSI (14): 89.44 (overbought)
- MACD: 0.66 / Signal: 0.44 / Histogram: 0.22 (bullish)
- Volume Analysis: Volume trends and institutional interest signals:
- On-Balance Volume (OBV): 38323921.00
- Volume Rate of Change: 388.79%
News & Sentiment Analysis
- Recent Headlines Summary: Key themes from last 10 news articles:
- Acquisition by Sanofi has a neutral sentiment
- Other recent news headlines have mixed sentiments, but none are strongly bearish or bullish
- Sentiment Assessment: Aggregate news sentiment: NEUTRAL (60% positive, 20% negative, 20% neutral)
- Catalyst Identification: Upcoming events:
- Earnings release on [Date]
- Market Narrative: News aligns with technical signals, suggesting a potential continuation of the uptrend
Risk & Volatility Assessment
- Beta Interpretation: Risk relative to market (beta = 0.54): Low volatility - stock moves less than market
- Volatility Regime: Current vs historical volatility levels:
- Average True Range (ATR): $0.53
- True Range: $0.04
- Options Market Signals: IV rank, put/call ratios, unusual activity:
- IV Rank: 76.2% (High)
- Put/Call Volume Ratio: 0.43 (Bullish sentiment)
Market Context & Positioning
- Sector Performance: Relative strength vs sector/market:
- Sector: Biotechnology
- Market: S&P 500
- Institutional Activity: Volume patterns suggesting institutional interest:
- Institutional ownership: [Data]
- Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- R-squared value: [Data]
Key Levels & Action Items
- Critical Price Levels: Support/resistance to monitor:
- Upper Bollinger Band: $14.06
- Middle Band: $11.37
- Lower Band: $8.68
- Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- SMA 20: $11.37
- EMA 12: $12.21
- Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- Earnings release on [Date]
- Risk Management: Stop-loss levels and position sizing considerations:
- Stop-loss at $13.50 (5% below current price)
- Position sizing: 2-3% of portfolio
Note: The analysis is based on the provided data, and any changes or updates to the data may affect the assessment.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-06 | Pre-Market | 9.82% | 3.74% | 0.38x | Within |
| 2024-11-07 | Pre-Market | 10.70% | 0.84% | 0.08x | Within |
| 2025-05-06 | After-Close | 7.10% | 10.31% | 1.45x | Exceeded |
| 2025-08-07 | After-Close | 16.27% | 6.60% | 0.41x | Within |
| 2025-11-05 | After-Close | 12.38% | 6.70% | 0.54x | Within |
- IV Rank (30D)
- 4.27
- IV Rank (7D)
- 100
- Avg IV
- 73.5%
- Straddle (30D)
- $3.08
- Straddle (7D)
- $2.50
- P/C Volume
- 3.63
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | WOLVERINE TRADING, LLC Custodian | $291.73K | 100.00% | 2025-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-02-11 | Deep Track Biotechnology Master Fund, Ltd. | 10%+ Owner | U | −47,179,047 | — | EDGAR | |
| 2026-02-10 | Emilio Emini | Director | Disp (D) | −10,075 | — | EDGAR | |
| 2026-02-10 | Scott Dunseth Myers | Director | Mixed | −35,004 | — | EDGAR | |
| 2026-02-10 | Joseph Anthony Metzinger | VP, Chief Accounting Officer | U | −7,129 | — | EDGAR | |
| 2026-02-10 | David F Novack | President & COO | Mixed | −63,334 | — | EDGAR | |
| 2026-02-10 | LAUREN P SILVERNAIL | Director | Disp (D) | −10,075 | — | EDGAR | |
| 2026-02-10 | Elaine D Sun | Director | Disp (D) | −29,865 | — | EDGAR | |
| 2026-02-10 | Ryan Spencer | CEO and Director | Mixed | −379,620 | — | EDGAR | |
| 2026-02-10 | DANIEL L KISNER | Director | Mixed | −23,329 | — | EDGAR | |
| 2026-02-10 | Brent MacGregor | Director | Disp (D) | −21,829 | — | EDGAR | |
| 2026-02-10 | FRANCIS CANO | Director | Disp (D) | −42,663 | — | EDGAR | |
| 2026-02-10 | John L Slebir | SVP General Counsel | Mixed | −69,634 | — | EDGAR | |
| 2026-02-10 | Kelly MacDonald | SVP and CFO | Mixed | −60,204 | — | EDGAR | |
| 2026-01-20 | David F Novack | President & COO | Mixed | — | $12.73 | -$662.7K | EDGAR |
| 2025-12-29 | John L Slebir | SVP General Counsel | Mixed | +32,056 | $15.38 | -$499.9K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | BVF INC/IL | 10%+ Owner | 1,179,292 | $18.28M | -$5.05M | 3 | 2009-08-03 |
| 2 | BIOTECHNOLOGY VALUE FUND L P | 1,098,392 | $17.03M | -$21.87M | 2 | 2009-08-10 | |
| 3 | Andrew A. F. Hack | Director | 925,714 | $14.35M | -$151.66M | 15 | 2023-08-10 |
| 4 | SYMPHONY CAPITAL GP, L.P. | Director | 903,143 | $14.00M | $0 | 1 | 2010-04-20 |
| 5 | BVF PARTNERS L P/IL | 10%+ Owner | 855,770 | $13.26M | -$20.11M | 1 | 2009-09-11 |
| 6 | Eddie Gray | CEO and Director | 304,597 | $4.72M | $80.1K | 19 | 2019-06-04 |
| 7 | MARK KESSEL | Director | 303,143 | $4.70M | -$28.36M | 7 | 2012-10-17 |
| 8 | Ryan Spencer | CEO and Director | 136,000 | $2.11M | -$1.13M | 21 | 2026-02-10 |
| 9 | MICHAEL S OSTRACH | Senior Vice President | 134,752 | $2.09M | -$695.6K | 34 | 2021-02-05 |
| 10 | Robert Janssen | SVP and CMO | 81,526 | $1.26M | -$5.42M | 54 | 2025-02-20 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-01-15 | DAVID NOVACK | Officer | 114,000 | $1.78M | 2026-01-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-29 | DAVID NOVACK | Officer | 30,000 | $464.7K | 2025-12-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-03-24 | DAVID NOVACK | Officer | 10,000 | $140.0K | 2025-03-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-03-18 | DAVID NOVACK | Officer | 14,020 | $190.4K | 2025-03-18 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-03-07 | DAVID NOVACK | Officer | 32,764 | $471.4K | 2025-03-07 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-03-01 | Burgess Justin | Officer | 20,526 | $262.4K | 2024-03-01 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-01-04 | Janssen Robert | Officer | 82,144 | $1.29M | 2024-01-04 | Pershing Advisor Solutions LLC, … | 10b5-1 | EDGAR |
| 2024-01-02 | DAVID NOVACK | Officer | 9,000 | $130.0K | 2024-01-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2023-12-01 | DAVID NOVACK | Officer | 20,000 | $271.1K | 2023-12-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2023-11-17 | Andrew A. F. Hack | Former Director | 81,250 | $1.10M | 2023-11-17 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| TTM Revenue | $0.3B |
| TTM Net Income | $-0.0B |
| TTM EPS | $-0.37 |